COMMUNIQUÉS West-GlobeNewswire

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
14/10/2025
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase [...]
Frontier Medicines Announces Third Precision Oncology Development Candidate
14/10/2025
- FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, targeting the largest genetic drivers of cancer - - Potential as a monotherapy and as a [...]
Nusano and Ariceum Therapeutics Announce Multi-Isotope Supply Agreement
14/10/2025
Agreement includes Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) to support Ariceum’s therapeutic programs WEST VALLEY CITY, Utah and BERLIN, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming [...]
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
14/10/2025
Completes clinical trials required by FDA for sNDA submission planned for the first quarter of 2026 NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical [...]
Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity
14/10/2025
– Financing led by new investor Bain Capital Private Equity with participation from new and existing investors to support continued development of a differentiated, late-stage portfolio of obesity treatments – – [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
14/10/2025
Company Announcement Net sales of DARZALEX ® in the third quarter of 2025 totaled USD 3,672 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
14/10/2025
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with [...]
PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities
14/10/2025
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most [...]
Soleo Health Introduces State-of-the-Art Pharmacy and Infusion Center in Washington, D.C., Area
14/10/2025
New Location Expands Service and Support to Patients Along Mid-Atlantic Corridor FRISCO, Texas and HERNDON, Va., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Soleo Health , a national provider of complex specialty pharmacy [...]
Teladoc Health Adds Workplace Safety Capability to its AI-Enabled Clarity™ Monitoring Solution for Hospitals and Health Systems
14/10/2025
New capability aims to address the growing threat of workplace violence in healthcare settings, building on the company’s suite of AI-enabled solutions that leverage purpose-built technology to transform care NEW YORK, [...]
Abalos Therapeutics Publishes in Cell Reports Medicine Validating ABX-001’s Potential to Overcome Cancer Immunotherapy Hurdles
14/10/2025
-- Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors -- Düsseldorf, Germany, October 14, 2025 – Abalos [...]
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
14/10/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Tan Shao Weng, Daniel [...]
Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
14/10/2025
ORION CORPORATION PRESS RELEASE 14 OCTOBER 2025 at 11.15 EEST Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025 Orion will publish Interim Report for January–September 2025 [...]
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
14/10/2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic [...]
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
14/10/2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic [...]
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases
14/10/2025
Press Release Press Release EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases Through this funding round, the company will initiate the clinical development of its first therapeutic [...]
CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells
14/10/2025
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue affecting many cancer drugs Lehi, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, October 14, [...]
Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611
14/10/2025
PARIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes [...]
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
14/10/2025
PRESS RELEASE AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH [...]

Pages